SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

SANGAMO THERAPEUTICS, INC

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026

$0.10−0.01 (-8.17%)

Close on Oct 19, 2026

Market cap: $39.43M
P/E (TTM): –
Dividend yield: –

SANGAMO THERAPEUTICS, INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	40	58	176	111	111	118	102	84	37	19	40	46	24	22	10	21	22
Research & Development	113	112	234	250	231	181	146	115	66	66	67	57	37	32	32	33	29
General & Administrative	35	45	61	63	63	67	62	47	27	26	19	16	14	12	14	13	13
Operating Expenses	161	162	450	313	294	248	208	162	93	92	86	73	51	44	46	46	42
Operating Income	-121	-104	-274	-201	-183	-130	-105	-77	-56	-73	-47	-27	-27	-22	-36	-25	-19
Interest & Investment Income	1.30	1.51	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-3.56	4.35	–	–	–	–	–	–	–	0.89	0.43	0.36	0.08	-0.07	0.07	0.08	0.55
Merger & Restructuring Charges	-0.55	0.34	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	13	5.52	89	0	0	0	0	0	–	–	–	–	0	–	–	–	–
Gain (Loss) on Sale of Assets	0	1.03	0	0	0.05	-0.22	-0.07	0	-0.01	–	–	0.10	0.10	-0.12	–	–	-0.03
Pretax Income	-124	-98	-263	-192	-178	-121	-95	-69	-55	-72	-46	-26	-27	–	–	–	–
Income Tax Expense	-0.57	-0.17	-5.07	0.43	0.31	0.35	0	0	0	-0.01	-5.72	0	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	-258	-192	-178	-121	-95	-69	-55	-72	–	–	–	–	–	–	–
Minority Interest in Earnings	–	–	0	0	-0.01	-0.13	-0.23	-0.56	0	–	–	–	–	–	–	–	–
Net Income	-123	-98	-258	-192	-178	-121	-95	-68	-55	-72	-41	-26	-27	-22	-36	-25	-19
EPS (Basic)(per share)	-0.44	-0.49	-1.48	-1.25	-1.23	-0.90	-0.85	-0.70	-0.70	-1.02	-0.58	-0.39	-0.48	-0.42	-0.71	-0.55	-0.44
EPS (Diluted)(per share)	-0.44	-0.49	-1.48	-1.25	-1.23	-0.90	-0.85	-0.70	-0.70	-1.02	-0.58	-0.39	-0.48	-0.42	-0.71	-0.55	-0.44
Shares Outstanding (Basic, Weighted)(shares)	280	202	174	154	145	134	112	97	78	71	70	67	56	53	51	45	–
Shares Outstanding (Diluted, Weighted)(shares)	280	202	174	154	145	134	112	97	78	71	70	67	56	53	51	45	–
EBITDA	-117	-99	-259	-189	-174	-124	-101	-75	-55	-72	-46	-26	-26	-22	-35	-24	-19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, TTM

Gross margin: –
Operating margin: -357.5%
Net margin: -356.9%
Return on equity, FY2025: -2891.8%

Financial strength

Current ratio: 0.70
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 51.9%

Valuation

P/E ratio: –
Price to sales: 1.14
Price to book: –
Dividend yield: –